Celldex Therapeutics, Inc. (CLDX)

NASDAQ: CLDX · IEX Real-Time Price · USD
39.63
+1.03 (2.67%)
At close: Apr 17, 2024, 4:00 PM
40.30
+0.67 (1.69%)
Pre-market: Apr 18, 2024, 4:25 AM EDT
2.67%
Market Cap 2.55B
Revenue (ttm) 6.88M
Net Income (ttm) -141.43M
Shares Out 64.42M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 889,388
Open 39.01
Previous Close 38.60
Day's Range 38.67 - 40.45
52-Week Range 22.11 - 53.18
Beta 1.56
Analysts Strong Buy
Price Target 66.00 (+66.54%)
Earnings Date May 2, 2024

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 10, 2008
Employees 160
Stock Exchange NASDAQ
Ticker Symbol CLDX
Full Company Profile

Financial Performance

In 2023, CLDX's revenue was $6.88 million, an increase of 192.02% compared to the previous year's $2.36 million. Losses were -$141.43 million, 25.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is $66.0, which is an increase of 66.54% from the latest price.

Price Target
$66.0
(66.54% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolv...

23 hours ago - GlobeNewsWire

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma ...

5 weeks ago - GlobeNewsWire

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflam...

6 weeks ago - GlobeNewsWire

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public off...

6 weeks ago - GlobeNewsWire

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,...

6 weeks ago - GlobeNewsWire

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market condit...

7 weeks ago - GlobeNewsWire

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - En...

7 weeks ago - GlobeNewsWire

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid ons...

7 weeks ago - GlobeNewsWire

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Ann...

2 months ago - GlobeNewsWire

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzo...

2 months ago - GlobeNewsWire

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx ...

5 months ago - GlobeNewsWire

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shar...

5 months ago - GlobeNewsWire

Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions

Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammator...

5 months ago - Market Watch

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups- -Mean change from baseline to week 12 ...

5 months ago - GlobeNewsWire

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

- Response observed as early as week 1 and durable for up to 16 weeks - - Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications - - Phase ...

5 months ago - GlobeNewsWire

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2 CSU enrollment complete; topline data by YE 2023 - - Phase 1b PN data accepted at World Congress on Itch -

5 months ago - GlobeNewsWire

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodu...

7 months ago - GlobeNewsWire

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conferenc...

7 months ago - GlobeNewsWire

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 - - First patient dosed in Phase 2 EoE study -

9 months ago - GlobeNewsWire

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvo...

10 months ago - GlobeNewsWire

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvol...

10 months ago - GlobeNewsWire

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 24, 55% of all patients with CSU in the ...

11 months ago - GlobeNewsWire

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company's barzolvolimab program will be presented at the European Academy o...

11 months ago - GlobeNewsWire

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on ...

11 months ago - GlobeNewsWire

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

HAMPTON, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-585. CDX-585 combines highly ac...

11 months ago - GlobeNewsWire